Hyperion to buy Israeli diabetes drug developer Andromeda Biotech
April 24, 2014 at 05:37 AM EDT
April 24 (Reuters) - U.S. biopharmaceutical company Hyperion Therapeutics said on Thursday it agreed to buy Israel's Andromeda Biotech, a developer of a new diabetes drug, in a deal that could be worth close to $600 million.